Showing results (1-10 of 145) with videos related to
Sort By:
Pageof 15
Agents and Actions. Supplements|January 1, 1992
The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitorsP A de Graeff, W H van GilstAgents and Actions. Supplements|January 1, 1992
Early ACE-inhibition in myocardial infarction. Possible role of bradykininW H van Gilst, P A de GraeffPharmacy World & Science : PWS|May 10, 2001
Comparative trials in registration files of cardiovascular drugs: comparator drugs and dosing schemesN F Wieringa, R Vos, P A de GraeffNederlands Tijdschrift Voor Geneeskunde|March 25, 1995
[Consensus heart failure. Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing]P A de Graeff, A H Balk, W J RemmeInternational Journal of Technology Assessment in Health Care|January 5, 2002
Assessment of new cardiovascular drugs. Relationships between considerations, professional characteristics, and prescribingN F Wieringa, P Denig, P A de Graeff, et al.Nederlands Tijdschrift Voor Geneeskunde|March 8, 1997
[Digoxin in chronic heart failure and sinus rhythm: is the end of the controversy in sight?]D J van Veldhuisen, P A de Graeff, H J CrijnsNetherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|February 20, 2015
Clinical relevance of the gap between pre-marketing trials and medical practice: the case of the cardiovascular drugsN F Wieringa, P Denig, P A de Graeff, et al.Henry Ford Hospital Medical Journal|January 1, 1992
PDN-21 (katacalcin) and chromogranin A: tumor markers for medullary thyroid carcinomaF Raue, E Blind, A GrauerEuropean Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|December 1, 1992
Determination of serum calcitonin by immunometric two-site assays in normal subjects and patients with medullary thyroid carcinomaA Zink, E Blind, F RauePageof 15